T. Rowe Price Associates
CMPX icon

T. Rowe Price Associates’s Compass Therapeutics CMPX Stock Holding History

T. Rowe Price Associates’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Buy
104,251
+4,729
+5% +$14K ﹤0.01% 2963
2026
Q1 		$527K Buy
99,522
+29,034
+41% +$168K ﹤0.01% 2432
2025
Q4 		$379K Buy
70,488
+13,900
+25% +$64.2K ﹤0.01% 2523
2025
Q3 		$199K Buy
56,588
+9,646
+21% +$30.5K ﹤0.01% 2795
2025
Q2 		$123K Hold
46,942
– – ﹤0.01% 2852
2025
Q1 		$90K Hold
46,942
– – ﹤0.01% 2841
2024
Q4 		$69K Buy
46,942
+11,326
+32% +$18.8K ﹤0.01% 2890
2024
Q3 		$66K Buy
35,616
+7,504
+27% +$9.35K ﹤0.01% 2892
2024
Q2 		$29K Buy
28,112
+4,057
+17% +$5.92K ﹤0.01% 2897
2024
Q1 		$48K Buy
24,055
+700
+3% +$1.21K ﹤0.01% 2876
2023
Q4 		$37K Buy
23,355
+2,892
+14% +$5K ﹤0.01% 2842
2023
Q3 		$41K Buy
20,463
+1,942
+10% +$4.8K ﹤0.01% 2797
2023
Q2 		$59K Buy
+18,521
New +$58.2K ﹤0.01% 2784

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's CMPX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Compass Therapeutics (CMPX) stake by 4.8% in Q2 2026, buying an estimated $14K and bringing the position to 104,251 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

T. Rowe Price Associates first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. The position peaked at $527K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • T. Rowe Price Associates held 104,251 shares of Compass Therapeutics worth $229K as of Q2 2026.
  • T. Rowe Price Associates bought 4,729 Compass Therapeutics shares in Q2 2026, an estimated $14K.
  • Compass Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2963 holding.
  • T. Rowe Price Associates first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Compass Therapeutics position peaked at $527K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.